Fig. 1
From: TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
Combination therapy with intra-tumoral ODN1826 and systemic CTLA-4 blockade cures bilateral B16-Ova melanoma. (a) C57BL/6 J mice were injected with 1.5 × 105 B16-Ova melanoma cells on the right and left flanks. The right flank tumor was then injected with 30μg of the TLR9 agonist ODN1826 or PBS in 50ul on days 3, 6 and 9 with or without concordant injection of 100μg of the CTLA-4 blocking antibody 9H10 i.p. Survival was monitored and mice were euthanized when tumors reached 1000mm3 on either flank. (b) Tumor growth was measured with calipers for the right (ODN1826 injected) and left (untreated) tumors and is plotted until the point at which any mice in the group died or their tumors on either flank reached 1000mm3. These data represent two experiments of 5 mice per group, all mice shown. Statistical significance was calculated using the log-rank (Mantel-Cox) test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001